Estrogen–DNA adducts are potential biomarkers for assessing the risk and development of estrogen-associated cancers. 4-Hydroxyequilenin (4-OHEN) and 4-hydroxyequilin (4-OHEQ), the metabolites of equine estrogens present in common hormone replacement therapy (HRT) formulations, are capable of producing bulky 4-OHEN–DNA adducts. Although the formation of 4-OHEN–DNA adducts has been reported, their quantitative detection in mammalian cells has not been done. To quantify such DNA adducts, we generated a novel monoclonal antibody (4OHEN-1) specific for 4-OHEN–DNA adducts. The primary epitope recognized is one type of stereoisomers of 4-OHEN–dA adducts and of 4-OHEN–dC adducts in DNA. An immunoassay with 4OHEN-1 revealed a linear dose–response between kn… Source: MedWorm: Oral Cancer
Tag: Novel
Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody
Tags: 4hydroxyequileninDNA, adducts, antibody, cells, Detection, immunoassay, mammalian, monoclonal, Novel, Quantitative, Using
Apoptosis induction of ZBB-006, a novel synthetic diterpenoid, in the human hepatocellular carcinoma cell line HepG2 in vitro and in vivo.
Authors: Fan QQ, Wang QJ, Zeng BB, Ji WH, Ji H, Wu YL
Diterpenes, present in many medicinal plants, have been the focus of continuous studies for the development of new anticancer agents. ZBB-006 is a new synthetic diterpenoid derivative which exhibited significant anti-proliferation activity against various cancer cell lines in our previous study. Here, we investigated the antitumor effect of ZBB-006 and its potential mechanisms in the human hepatocellular carcinoma cell line HepG2, both in vitro and in vivo. We found that oral administration of ZBB-006 effectively suppressed the growth of HepG2 xenograft tumor in nude mice without body weight decline, compared with the control group. Meanwhile, the growth inhibitory effect of ZBB-006 on HepG2 cells was observed with MTT assay. Then a…
Source: MedWorm: Oral Cancer
Tags: Apoptosis, carcinoma, cell, diterpenoid, hepatocellular, HepG2, human, Induction, line, Novel, synthetic, vitro, vivo, ZBB006
Leptotrichia hongkongensis sp. nov., a novel Leptotrichia species with the oral cavity as its natural reservoir.
Authors: Woo PC, Wong SS, Teng JL, Leung KW, Ngan AH, Zhao DQ, Tse H, Lau SK, Yuen KY
A straight, non-sporulating, Gram-variable bacillus (HKU24(T)) was recovered from the blood culture of a patient with metastatic breast carcinoma. After repeated subculturing in BACTEC Plus Anaerobic/F blood culture broth, HKU24(T) grew on brucella agar as non-hemolytic, pinpoint colonies after 96 h of incubation at 37 degrees C in an anaerobic environment and aerobic environment with 5% CO(2). Growth was enhanced with a streak of Staphylococcus aureus. HKU24(T) was non-motile and catalase-negative, but positive for alkaline phosphatase, beta-glucosidase, and alpha-glucosidase. It hydrolyzed phenylphosphonate and reduced resazurin. 16S rRNA, groEL, gyrB, recA, and rpoB sequencing showed that HKU24(T) …
Source: MedWorm: Oral Cancer
Tags: Cavity, hongkongensis, Leptotrichia, Natural, nov., Novel, Oral, reservoir., species
Downregulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract
This study was undertaken to identify the genes in response to areca nut extract, a potential carcinogen of oral cancer.Two oral cancer sublines chronically treated with areca nut extract were established. Methods such as microarray and immunohistochemistry were used to screen and validate the genes’ altered expressions in areca nut extract-sublines or in cancer tissues.A total of 35 genes were differentially expressed in both sublines. Several functional pathways were significantly altered. Six genes were confirmed over 2-fold of changes, including Ches1. Functional analyses showed that overexpression of Ches1 suppressed cell growth and arrested cells in the G2/M phase. Consistently, this gene has reduced expression in 52% of oral cancer tissues, which was significantly correlated with th…
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Source: MedWorm: Oral Cancer
Tags: areca, Cancer, cells, Ches1, chronically, Downregulation, exposed, extract, Genes, Novel, Oral
Genta Initiates Once-Weekly Treatment Schedule For Tesetaxel, A Novel Oral Tubulin Inhibitor, In New Dose-Ranging Study
Genta Incorporated (OTCBB: GETA) announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel — a late Phase 2 oncology product — is the leading oral taxane currently in clinical development. Genta has recently completed a dose-ranging and pharmacokinetic study using tesetaxel administered once every 3 weeks, a schedule that has shown anticancer activity in several Phase 2 clinical trials… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: DoseRanging, Genta, Inhibitor, Initiates, Novel, OnceWeekly, Oral, Schedule, Study, Tesetaxel, Treatment, Tubulin
Oral cancer study shows full tumor genome; novel method speeds analysis for individualized medicine
Researchers are reporting on the application of a new approach for sequencing RNA to study cancer tumors. (Source: ScienceDaily Headlines)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: analysis, Cancer, full, genome, individualized, medicine, method, Novel, Oral, shows, Speeds, Study, tumor
Progenics Presents Novel Multiplex PI3-Kinase Inhibitors At American Association For Cancer Research Conference On Protein Translation And Cancer
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells. The compounds were identified as part of the Company’s ongoing oncology drug discovery efforts. The data are being presented in both oral and poster sessions at the American Association for Cancer Research (AACR) conference on Protein Translation and Cancer in Coronado, CA… (Source: Health News from Medical News Today) Source: MedWorm: Oral Cancer
Tags: American, Association, Cancer, Conference, Inhibitors, Multiplex, Novel, PI3Kinase, Presents, Progenics, Protein, research, Translation